Scarica l'app Stockscreener
10.03
12.70%
1.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Precedente Chiudi:
$8.90
Aprire:
$8.62
Volume 24 ore:
4.51M
Relative Volume:
1.52
Capitalizzazione di mercato:
$1.35B
Reddito:
$24.30M
Utile/perdita netta:
$-145.57M
Rapporto P/E:
-7.5414
EPS:
-1.33
Flusso di cassa netto:
$-149.17M
1 W Prestazione:
+22.77%
1M Prestazione:
+11.57%
6M Prestazione:
+430.69%
1 anno Prestazione:
+176.31%
Intervallo 1D:
$8.53
$10.07
Intervallo di 1 settimana:
$7.69
$10.07
Portata 52W:
$1.03
$10.07
Tango Therapeutics Inc Stock (TNGX) Company Profile
Nome
Tango Therapeutics Inc
Settore
Industria
Telefono
(857) 320-4900
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Confronta TNGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
10.03 | 1.20B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-17 | Iniziato | Jefferies | Buy |
| 2024-04-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Iniziato | Piper Sandler | Overweight |
| 2023-12-08 | Iniziato | B. Riley Securities | Buy |
| 2022-10-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
Novavax, UniFirst, and More Stocks See Action From Activist Investors - Barron's
Tango Therapeutics stock hits 52-week high at 9.7 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal TestingBuy (TNGX) - Seeking Alpha
Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? - Zacks Investment Research
Tango Therapeutics launches $100M at-the-market stock offering - MSN
Tango Therapeutics Inc files for mixed shelf offeringSEC filing - MarketScreener
Tango Therapeutics files prospectus for resale of 1.7 million shares by selling stockholderSEC filing - MarketScreener
Tango Therapeutics launches new $100 million at-the-market stock offering - Investing.com Nigeria
Tango Therapeutics Enters New Sales Agreement with Leerink - TipRanks
[S-3] Tango Therapeutics, Inc. Shelf Registration Statement | TNGX SEC FilingForm S-3 - Stock Titan
[8-K] Tango Therapeutics, Inc. Reports Material Event | TNGX SEC FilingForm 8-K - Stock Titan
Tango Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Why Tango Therapeutics Inc. stock remains on watchlists2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com
Short interest data insights for Tango Therapeutics Inc.Weekly Trade Review & Accurate Intraday Trade Tips - newser.com
How analysts rate Tango Therapeutics Inc. stock todayWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
Will Tango Therapeutics Inc. stock benefit from automationForecast Cut & Short-Term Trading Alerts - newser.com
TNGX: Vopimetostat advances in pivotal and combo studies, with strong efficacy and cash runway into 2028 - TradingView
Long term hold vs stop loss in Tango Therapeutics Inc.July 2025 Analyst Calls & Safe Capital Growth Plans - newser.com
Why Tango Therapeutics Inc. is moving todayPortfolio Return Report & Free Reliable Trade Execution Plans - newser.com
Wolfe Research Initiates Coverage of Tango Therapeutics (TNGX) with Peer Perform Recommendation - Nasdaq
B. Riley Securities Maintains Tango Therapeutics (TNGX) Buy Recommendation - Nasdaq
Wolfe Research Initiates Coverage on Tango Therapeutics (TNGX) | - GuruFocus
Tango Therapeutics price target raised to $14 from $8 at B. Riley - TipRanks
B. Riley Adjusts Price Target on Tango Therapeutics to $14 From $8, Maintains Buy Rating - MarketScreener
Will Tango Therapeutics Inc. stock maintain dividend yieldInsider Selling & Reliable Breakout Forecasts - newser.com
Using AI based signals to follow Tango Therapeutics Inc.2025 Macro Impact & Short-Term High Return Strategies - newser.com
Does Tango Therapeutics Inc. fit your quant trading modelMarket Growth Report & Daily Market Momentum Tracking - newser.com
Can Tango Therapeutics Inc. stock outperform in 2025 bull marketWeekly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
How Tango Therapeutics Inc. stock performs in rising dollar environment2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Why Tango Therapeutics Inc. stock is trending among retail tradersWeekly Market Outlook & Daily Volume Surge Trade Alerts - newser.com
Will Tango Therapeutics Inc. stock attract ESG investorsMarket Rally & Daily Profit Maximizing Trade Tips - newser.com
Tango Therapeutics’ Promising Update on TNG260 Clinical Study - MSN
Tango Therapeutics (TNGX): Evaluating Valuation Following Strong Revenue Growth and Doubling Share Price - Yahoo Finance
How Investors May Respond To Tango Therapeutics (TNGX) Posting First Profit on Surging Q3 Revenue - Yahoo Finance
Tango Therapeutics Inc Azioni (TNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):